Cover Image
市場調查報告書

肢端肥大症:開發中產品分析

Acromegaly - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192431
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
肢端肥大症:開發中產品分析 Acromegaly - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 91 Pages
簡介

肢端肥大症,是成人期垂體生長激素過剩而發病的荷爾蒙障礙。有體臭,容易累,頭痛,巨大的腳,身長過高,關節周圍的骨頭部位腫,牙齒的間隔寬廣,睡眠呼吸中止症等症狀。治療中,包含外科手術,多巴胺促效劑,生長激素拮抗劑等。

本報告提供肢端肥大症的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

肢端肥大症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Aegis Therapeutics, LLC
  • Antisense Therapeutics Limited
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • DexTech Medical AB
  • Foresee Pharmaceuticals, LLC
  • Glide Pharmaceutical Technologies Limited
  • Ionis Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Italfarmaco S.p.A.
  • Novartis AG
  • Peptron, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ATL-1103
  • BIM-23A758
  • COR-005
  • FP-002
  • G-02113
  • ISIS-GHRLRx
  • ITF-2984
  • L-779976
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate
  • octreotide acetate long acting
  • octreotide acetate SR
  • octreotide SR
  • pasireotide ER
  • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors
  • Somadex
  • SXN-101742
  • SXN-101959

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8480IDB

Summary

Global Markets Direct's, 'Acromegaly - Pipeline Review, H2 2016', provides an overview of the Acromegaly pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acromegaly
  • The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects
  • The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acromegaly

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acromegaly
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acromegaly Overview
  • Therapeutics Development
    • Pipeline Products for Acromegaly - Overview
    • Pipeline Products for Acromegaly - Comparative Analysis
  • Acromegaly - Therapeutics under Development by Companies
  • Acromegaly - Therapeutics under Investigation by Universities/Institutes
  • Acromegaly - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acromegaly - Products under Development by Companies
  • Acromegaly - Products under Investigation by Universities/Institutes
  • Acromegaly - Companies Involved in Therapeutics Development
    • Aegis Therapeutics, LLC
    • Amryt Pharma plc
    • Antisense Therapeutics Limited
    • Chiasma, Inc.
    • Crinetics Pharmaceuticals, Inc.
    • DexTech Medical AB
    • Foresee Pharmaceuticals, LLC
    • Glide Pharmaceutical Technologies Limited
    • Ionis Pharmaceuticals, Inc.
    • Ipsen S.A.
    • Italfarmaco S.p.A.
    • Midatech Pharma Plc
    • Novartis AG
    • Peptron, Inc.
    • Strongbridge Biopharma plc
    • Sun Pharma Advanced Research Company Ltd.
  • Acromegaly - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atesidorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COR-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-GHRLRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITF-2984 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-779976 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate long acting - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • octreotide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Somadex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SXN-101959 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acromegaly - Dormant Projects
  • Acromegaly - Discontinued Products
  • Acromegaly - Product Development Milestones
    • Featured News & Press Releases
      • Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
      • Jul 13, 2016: ATL1103 Patent Update
      • Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
      • Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
      • Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
      • May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
      • May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
      • May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
      • Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
      • Apr 18, 2016: Chiasma Provides Update Regarding FDA's Complete Response Letter for Mycapssa New Drug Application
      • Apr 15, 2016: FDA Issues Complete Response Letter for Mycapssa New Drug Application
      • Mar 14, 2016: Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
      • Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference
      • Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced
      • Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acromegaly, H2 2016
  • Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acromegaly - Pipeline by Aegis Therapeutics, LLC, H2 2016
  • Acromegaly - Pipeline by Amryt Pharma plc, H2 2016
  • Acromegaly - Pipeline by Antisense Therapeutics Limited, H2 2016
  • Acromegaly - Pipeline by Chiasma, Inc., H2 2016
  • Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
  • Acromegaly - Pipeline by DexTech Medical AB, H2 2016
  • Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016
  • Acromegaly - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
  • Acromegaly - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Acromegaly - Pipeline by Ipsen S.A., H2 2016
  • Acromegaly - Pipeline by Italfarmaco S.p.A., H2 2016
  • Acromegaly - Pipeline by Midatech Pharma Plc, H2 2016
  • Acromegaly - Pipeline by Novartis AG, H2 2016
  • Acromegaly - Pipeline by Peptron, Inc., H2 2016
  • Acromegaly - Pipeline by Strongbridge Biopharma plc , H2 2016
  • Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acromegaly - Dormant Projects, H2 2016
  • Acromegaly - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acromegaly, H2 2016
  • Number of Products under Development for Acromegaly - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top